Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer

Anticancer Research

Volumn 20, Issue 3 B, 2000, Pages 2009-2013

  Papathoma, A S ^a,c   Petraki, C ^b   Grigorakis, A ^b   Papakonstantinou, H ^b   Karavana, V ^b   Stefanakis, S ^b   Sotsiou, F ^b   Pintzas, Alexander ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Bladder cancer; Gelatinases; Metastasis; MMP 2; MMP 9

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE;

ADULT; AGED; ARTICLE; BASEMENT MEMBRANE; BLADDER CANCER; CANCER GRADING; CANCER INVASION; CLINICAL ARTICLE; EXTRACELLULAR MATRIX; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; STATISTICS; ZYMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0033898366     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. De Clerck YA, Shimada H, Taylor SM and Langley KE: Matrix metalloproteases and their inhibitors in tumor progression. Ann NY Acad Science 732: 222-232, 1994.
2. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation Cell 64: 327-336, 1991.
3. Massova I, Kotra LP, Fridman R and Mobashery S: Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 12: 1075-1095, 1998.
4. Matrisian LM: The matrix degrading metalloproteinases. Bioassays 14: 455-463, 1992.
5. Opdenakker G and Van Damme J: Chemotactic factors, passive invasion and metastasis of cancer cells. Immunology Today 13: 463-464, 1992.
6. Pyke C, Rafliaer E, Huhtala P, Hurslainen T, Dano K and Tryggvason K: Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res 52: 1336-1341, 1992.
7. Overall CM, Wrana JL and Sodek J: Transcriptional and post-transcriptional regulation of the 72kDa gelatinase/type IV gollagenase by transforming growth factor β1 in human fibroblasts. Comparison with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem 266: 14064-14071, 1991.
8. Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, Seltzer JL, Kronberg A, He C, Bauer E and Goldberg GI: H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen J Biol Chem 63: 6579-6587, 1988.
9. Hipps DS, Hembry RM, Docherty, AJ, Reynolds JJ and Murphy G: Purification and characterization of human 72-kDa gelatinase (type IV collagenase). Use of immunolocalisation to demonstrate the non-coordinate regulation of the 72-kDa and 95-kDa gelatinases by human fibroblasts. Biol Chem Hoppe Seyler 372: 287-296, 1991.
10. Kanayama H, Yokota K, Kurokawa Y Murakami Y, Nishitani M and Kagawa S: Prognostic values of matrix metallotroteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 82: 1359-1368, 1998.
11. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A and Balkwill F: Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Research 53: 5365-5369, 1993.
12. Hsu HC, Kao MT and Lin YH: Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase technique: A comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580, 1981.
13. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD and Balkwill FR. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 67: 1126-1131, 1993.
14. Brown PD, Levy AT, Margulies IMK, Liotta LA and Stetler-Stevenson WG: Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res 50: 6184-6191, 1990.
15. Murphy WM, Beckwith JB and Farrow GM: Tumours of the urinary bladder. In: Tumors of the kidney, bladder, and related urinary structures, Rosai J. (ed) 1994, pp 193-297. AFIP: Washington
16. nd revision. Springer-Verlag: Berlin, 1992.
17. Takashi M, Murase T, Mizuno S, Hamajima N and Ohno Y: Multivariate evaluation of prognostic determinants in bladder cancer patients. Urol Int 42: 368-374, 1987.
18. Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F, Pontes JE, Crissman JC and Fridman R: High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 56: 1654-1659, 1996.
19. Liu BC and Liotta LA: Biochemistry of bladder cancer invasion and metastasis. Clinical implications. Urol Clin North Am 19: 621-627, 1992.
20. Liu BC: Commentary on metalloproteinases and bladder carcinoma J Urol 160: 1219, 1998.
21. Angulo JC, Lopez JL, Flores N and Toledo JD: The value of tumor spread grading and growth pattern as morphological predictive parameters in bladder carcinoma. A critical revision of the 1987 TNM classification. J Cancer Res Clin Oncol 199: 578-593, 1993.
22. Jordan A M, Weingarten J and Murphy WM: Transitional cell neoplasms of the urinary bladder cancer: can biological potential be predicted from histological grading? Cancer (Phila) 60: 2766-2774, 1987.
23. Grignon DJ: Neoplasms of the urinary bladder. In Urological surgical pathology, Bostwick DG, Eble NJ (eds). Moshy: St Louis, Baltimore, Boston, Carlsbad, Chicago, Naples, New York, Philadelphia, Portland, London, Madrid, Mexico City, Singapore, Sydney, Tokyo, Toronto, Wiesbaden, 1997, pp 215-305.
24. Garbisa S, Pozzatti R, Muschel RJ, Saffioti U, Ballin M, Goldfarb RH, Khoury G and Liotta LA: Secretion of type IV collagenolytic protease and metastatic phenotype induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-Ela. Cancer Res 47: 1523-1528, 1987.
25. Monteagudo C, Merino MJ, San-Juan J, Liotta LA and Stetler-Stevenson WG: Immunohistochemical distribution of type IV collagenase in normal, benign and malignant breast tissue. Am J Pathol 136; 585-592, 1990.
26. Pyke C, Ralfliaer E, Tryggvason K and Dano K: Messenger RNA for two type IV collagenases in stromal cells in human colon cancer Am J Pathol 142: 359-364, 1993.
27. Stearns ME and Wang M, Type IV collagenase (Mr 72,000) expression in human prostate: benign and malignant tissue. Cancer Res 53: 878-883, 1993.
28. Remacle AG, Noel A, Duggan C, Mc Dermott E, O'Higgins N, Foidart JM and Duffy MJ: Assay of matrix metalloproteinases type 1,2,3 and 9 in breast cancer. Br J Cancer 77: 926-931, 1998.
29. Gohji K, Fujimoto N, Ohkawa J, Fuji A and Nakajima M: Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br J Cancer 77: 650-655, 1998.
30. Gohji K, Fujimoto N, Komiyama T, Fujii A, Ohkawa J, Kamidono S and Nakajima M: Elevation of serum levels of matrix metalloproteinase-2 and-3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 78: 2379-2387, 1996.
31. Kawamata H, Kameyama S, Kawai K Tanaka Y, Nan L, Barch DH, Stetler-Stevenson WG and Oyasu R: Marked acceralation of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A. In J Cancer 63: 568-575, 1995.
32. Margulies IM, Hoyhtya M, Evans C, Stracke ML, Liotta LA and Stetler-Stevenson WG: Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiol Biomarkers Prev 1: 467-474, 1992.
33. Gohji K, Fujimoto N, Fujii A, Komiyama T, Okawa J and Nakajima M: Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases 2 ratio in recurrence of urothelial cancer afler complete resection. Cancer Res 56: 3196-3198, 1996.